Cytokinetics
CYTK
101 hedge funds and large institutions have $141M invested in Cytokinetics in 2013 Q3 according to their latest regulatory filings, with 69 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 7 closing their positions.
886% more first-time investments, than exits
New positions opened: 69 | Existing positions closed: 7
273% more call options, than puts
Call options by funds: $4.75M | Put options by funds: $1.27M
159% more funds holding
Funds holding: 39 → 101 (+62)
19% more capital invested
Capital invested by funds: $119M → $141M (+$22.1M)
15% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 13
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.9M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$9.49M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$8.02M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.59M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
+$7.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$20.6M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$2.34M |
| 3 |
GACM
Green Arrow Capital Management
New York
|
-$2.15M |
| 4 |
PAA
Peregrine Asset Advisers
Portland,
Oregon
|
-$530K |
| 5 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$482K |
CYTK Hedge Fund Activity: Q3 2013 in Review
101 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q3 2013, worth a combined $141M — up 19% from $119M a quarter earlier.
Buyers outnumbered sellers: 69 funds opened new CYTK positions and 7 closed out — a net gain of 62 holders — while 15 added to existing stakes and 13 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $19.9M. The largest seller was Deerfield Management, exiting entirely with an estimated $20.6M sold.
- 101 institutional investors held Cytokinetics (CYTK) as of Q3 2013, up from 39 in Q2 2013.
- Funds reported $141M of Cytokinetics stock for Q3 2013, up 19% quarter-over-quarter.
- 69 funds opened new Cytokinetics positions in Q3 2013 and 7 closed out, a net change of +62 holders.
- The largest Cytokinetics buyer in Q3 2013 was Fidelity Investments, an estimated $19.9M added.
- The largest Cytokinetics seller in Q3 2013 was Deerfield Management, an estimated $20.6M sold.
Based on aggregated 13F filings for Q3 2013.